Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
Posted on: Thursday, 30 August 2007, 06:19 CDT
PRINCETON, N.J., Aug. 30 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that it is scheduled to present at the Thomas Weisel Partners Healthcare Conference at 11:30 AM Eastern Time on Wednesday, September 5, 2007. The conference is being held at the Four Seasons Hotel in Boston, Massachusetts. Medarex's presentation will be webcast live and will be available for replay through the Webcast page in the Investor Relations section of the Medarex website via the Internet at http://www.medarex.com/.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com/.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, x2216 or Jean Mantuano,Corporate Communications, media, x2221, both of Medarex, Inc., +1-609-430-2880
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html
Source: PRNewswire-FirstCall
Related Articles
- Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
- Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
- ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
- Novavax Announces Favorable Interim Results From Human Clinical Trial for Its Pandemic Influenza Vaccine Program
- Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose(TM)
- Medarex Announces Initiation of Phase I Clinical Trial for the Treatment of Psoriasis
- Investigational Drug Targeting Inflammatory Bowel Disease Enters Second Human Clinical Trial
- Microbia Raises $75 Million in Private Equity Financing to Advance Therapeutic Candidates Through Clinical Trials
- eFoodSafety.Com, Inc. Commences Human Clinical Trials on Cinnergen Diabetes Product
- Array BioPharma's Anticancer Compound ARRY-334543 Cleared to Advance Into Human Clinical Trials
 |
 |
User Comments (0)
RSS Feeds